A Preliminary Study of D-Cycloserine Augmentation of Cognitive-Behavioral Therapy in Pediatric Obsessive-Compulsive Disorder

Publisher Website
Google Scholar
Abstract
No abstract available
Funding Information
  • National Institutes of Health (MH076775, L40 MH081950-02)
  • National Alliance for Research on Schizophrenia and Affective Disorders
  • National Institute of Mental Health
  • National Institute of Child Health and Human Development
  • All Children's Hospital Research Foundation
  • Centers for Disease Control
  • National Alliance for Research on Schizophrenia and Affective Disorders
  • Obsessive-Compulsive Foundation
  • Tourette Syndrome Association
  • Janssen Pharmaceuticals
  • Foundation for Research on Prader-Willi Syndrome
  • NIMH
  • Forest Laboratories
  • Janssen Pharmaceuticals
  • Endo
  • Obsessive-Compulsive Foundation
  • Tourette Syndrome Association
  • All Children's Hospital Research Foundation
  • Centers for Disease Control
  • National Alliance for Research on Schizophrenia and Affective Disorders
  • National Alliance for Research on Schizophrenia and Affective Disorders
  • International OCD Foundation
  • Joseph Drown Foundation
  • Friends of the Semel Institute
  • NIMH
  • AstraZeneca
  • Lilly
  • McNeil Pediatrics
  • Shire
  • Forest Laboratories, Inc.
  • Sanofi Aventis
  • Janssen
  • Bristol-Myers Squibb
  • Pfizer
  • NIMH
  • NIMH
  • Michael A. Jenike Endowed Fund
  • NIMH
  • the Food and Drug Administration
  • Obsessive-Compulsive Foundation
  • Tourette Syndrome Association
  • Elsevier Publications
  • Guilford Publications
  • New Harbinger Publications
  • Boehringer Ingelheim
  • National Institute of Neurological Disorders and Stroke
  • NIMH
  • Eli Lilly and Co.
  • Forest Laboratories
  • GlaxoSmithKline
  • Pfizer, Boehringer Ingelheim
  • Otsuka
  • Obsessive-Compulsive Foundation
  • Tourette Syndrome Association
  • Wallace Foundation
  • Pediatric Obsessive Compulsive and Related Disorders
  • McIngvale Family Foundation